# Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/once-weekly-tirzepatide-versus-once-daily-insulin-degludec-as-add-on-to/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Bernhard Ludvik,Francesco Giorgino,Esteban Jódar,Juan P. Frías,Laura Fernández Landó,Katelyn Brown,Ross Bray,Ángel Rodríguez |
| Citations | 621 |
| DOI | 10.1016/s0140-6736(21)01443-4 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3191712049 |
| PMID | 34370970 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Bernhard Ludvik](https://scholariq.org/researchers/bernhard-ludvik/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Gastrointestinal motility and disorders](https://scholariq.org/topics/gastrointestinal-motility-and-disorders/)
- [Nausea and vomiting management](https://scholariq.org/topics/nausea-and-vomiting-management/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.